About Sunshine Heart

C-Pulse Device

Executive Team

Sunshine Heart's employees have a wealth of experience in medical technology and heart assist therapy development and commercialization.

Sunshine Heart has a world class team dedicated to commercializing the C-Pulse® System.

 


David Rosa

Chief Executive Officer; Board of Directors

Dave Rosa is Sunshine Heart's Chief Executive Officer. Mr. Rosa has spent the past 19 years in a variety of positions in the medical device industry. He was appointed CEO in October of 2009.

Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Rosa was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he directed the launch of twenty seven new products within the Company's cardiovascular division.

From 1999-2004, Rosa held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that designs, develops and commercializes percutaneously placed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Senior Vice President of Marketing and Business Development, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, he served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific.

Mr. Rosa holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.

 


William Peters, MD

Chief Technology Officer

William Peters, MD, invented the proprietary C-Pulse technology and served as Sunshine Heart’s initial CEO upon co-founding the Company in 1999. As Chief Technical Officer, he is responsible for C-Pulse’s ongoing technological development and clinical application as an innovative technology for treating moderate heart failure.

In addition to C-Pulse, Dr. Peters has developed a number of other successful cardiac technology innovations, including an endovascular cardiopulmonary bypass system for minimally invasive cardiac surgery, which was commercialized by Heartport Inc., a NASDAQ-listed company that later was acquired by Johnson & Johnson.

Dr. Peters has been the lead or co-author of more than 20 published articles, and contributed chapters to four books regarding cardiac surgery and heart failure. He has extensive clinical experience in thoracic transplantation and a variety of heart failure technologies, including intra-aortic balloon pump systems and left-ventricular assist devices (LVADs) from such companies as Biomedicus, Abiomed, Thoratec and World Heart-Novacor. He has an honorary appointments with the University of Auckland's department of surgery and biomedical engineering, providing supervision of doctoral candidates. He is also a senior clinical research fellow in cardiothoracic surgery, based at Auckland City Hospital. These roles afford Sunshine Heart a direct view of the latest developments, particularly in the fields of congestive heart failure and biomedical engineering advancement. Dr. Peters served on the board until January 2013.

 


Patrick Verta, MD

Chief Medical Officier

Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings over 20 years of experience in the medical field with the majority of time spent in the cardiovascular field.

Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of Clinical Affairs at Neomend, a medical device company that developed and commercialized the only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The company was acquired by Bard/Davol in October 2012.

Before Neomend, he served as Medical Director of Clinical Research and Business Development at Abbott Vascular, where he played a critical role in the approval of several stent systems used in peripheral vascular disease, in particular carotid artery stenosis, renal artery stenosis, and peripheral Artery Disease (PAD). While at Abbott, Dr. Verta led the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) PMA, the largest randomized carotid trial ever, enrolling over 2,500 patients and considered today to be the gold standard for carotid stenting trials. Prior to Abbott, Dr. Verta held the position of Endovascular Clinical Science and Biometrics Director at Guidant Corporation.

In addition to his experience driving clinical trials, he has co-authored seventeen manuscripts on novel medical device therapies in peer-review journals, and is credited with two patents in the data management and electronic data capture areas. Dr. Verta holds a Doctorate of Medicine from the Faculté de Médecine in Paris, France; as well as a Doctorate of Veterinary Medicine from the Ecole Nationale Vétérinaire d’Alfort, France. He also completed a Masters Degree in Biostatistics at the University of Paris.

 

 

Debra Kridner

Executive Vice President of Regulatory Affairs

Debra Kridner joined Sunshine Heart in November 2009 as Vice President, Clinical Research and Regulatory Affairs. Kridner brings more than 30 years of experience in clinical research, quality and regulatory affairs for the medical device industry.

Prior to joining Sunshine Heart, Kridner owned a consulting firm focused on clinical research and regulatory affairs. Before founding her own business, she served as Vice President, Clinical Research and Regulatory Affairs for Cardiac Surgery and Interventional Cardiology for the Cardiovascular Division of St. Jude Medical, Inc. Prior to St. Jude, Kridner held senior management positions in clinical, regulatory, and quality at Medtronic in the areas of cardiac surgery and neurology.

In addition Kridner also held executive management position as the Vice President of Regulatory and Quality for Medsource, an eleven facility medical device contract manufacturer. Her career also included several medical and scientific research and development companies including Edwards Lifescience/Baxter Edwards and, Gish Biomedical.

Debra is also on the Advisory Board for the St. Cloud University Masters Degree Program for Clinical Research and Regulatory Affairs. Kridner holds a B.A. in Biology from University of California Fullerton.

 

Kevin Bassett

Kevin Bassett

Sr. Vice President of Technology & Operations

Kevin Bassett joined Sunshine Heart in October 2010 as Vice President of Research, Development, and Quality Assurance.

Prior to joining Sunshine Heart, Mr. Bassett was Sr. Vice President of Operations, Development, and Quality Assurance at Acorn Cardiovascular, an early-stage medical device company developing passive restraint therapies to treat heart failure. During his seven years with Acorn, he served in a variety of executive level positions encompassing operations, research, development, quality, manufacturing and finance.

From 1997-2004, Mr. Bassett was a Co-founder and Principal at St. Paul Consulting LLC, a firm focused on the medical device and pharmaceutical industries and specializing in operations, development, regulatory affairs, and quality assurance. From 1994-1997 he served as a Senior Consultant and Manager in the management consulting division of Grant Thornton LLC. From 1992-1994 Mr. Bassett was a Senior Consultant at Andersen Consulting LLC (now Accenture LLC).

Mr. Bassett is a certified public accountant (inactive license). He holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. degree in Accounting and English from St. John’s University. Mr. Bassett also held a commission as an officer in the United States Army Reserves from 1991 – 2001.

 


Jeff Mathiesen

Chief Financial Officer

Jeff Mathiesen joined Sunshine Heart as Chief Financial Officer (CFO) in March 2011. He brings more than 20 years experience as a finance and operations officer with extensive background managing finance, manufacturing, administration, information technology, human resources, investor relations and risk management functions in diverse, publicly and privately held companies.

Prior to Sunshine Heart, Mathiesen served as Vice President and CFO for Zareba® Systems, Inc., a publicly held manufacturer and marketer of medical products, perimeter fencing and security systems. At Zareba, he helped the company change course and return to profitability, led the divestiture of two business units and helped negotiate the sale of the company to Woodstream Corp., a long-standing, privately held company.

Before Zareba® Systems, Mathiesen had served in numerous other finance and operations leadership roles in high growth, technology based, publicly held companies with operations around the globe. His experience includes several public and private equity financings including an IPO, and various M&A transactions. Previous positions held by Mathiesen include Vice President and CFO for Delphax Technologies, Inc.; Vice President of Business Development, Vice President, and CFO for Micro Component Technology, Inc.; Vice President and CFO Recovery Engineering, Inc., subsequently acquired by Proctor & Gamble; Corporate Controller at Osmonics, Inc., subsequently acquired by General Electric Company; and Aslesens, Inc., as a controller.

Mathiesen is a certified public accountant who started his career at Deloitte & Touche, LLP, after completing a B.S in Accounting at the University of South Dakota.

 


Jim Yearick

Vice President of Marketing and Sales

Jim Yearick joined Sunshine Heart as Vice President of Marketing and Sales, October, 2011. He brings 19 years of medical device leadership in marketing/sales management.

Prior to joining Sunshine Heart, Yearick held executive roles for 8 years at Medtronic’s Cardiac Rhythm Disease Management Division. From 2008-2011 he was Vice President of Global Product Marketing managing the Therapy Product lines, Healthcare Economics, Reimbursement, Pricing, International Marketing and U.S. Field Marketing. From 2005-2008, Yearick served as the Vice President, Asia with General Management responsibility for 4 regions spanning 12 countries and was based out of Hong Kong. Previous to this role he was a Field Director for the Eastern Region.

In addition, Yearick held Marketing and Sales leadership roles with Genzyme (2000-2003) as Director of International Markets and previous to that was with Boston Scientific (1992 – 2000) in a variety of roles. Previous to joining the medical device field he held leadership roles with both Unilever and Procter & Gamble.

Yearick holds an MBA from Northeastern University and a BSBA Degree from the University of Delaware.